M.S.D. LIMITED

To exchange views on EU pharmaceutical policy issues that may arise during the Irish EU Presidency, matters affecting the life sciences sector in Europe, and the proposed establishment of an EU Pharmaceutical Task Force.

To provide political stakeholders in Co. Meath with an overview of MSD Dunboyne's operations and contribution to Ireland's life sciences sector and to exchange views on issues relevant to the competitiveness of the pharmaceutical industry in Ireland and the EU.

To raise issues relating to capacity constraints within the National Pulmonary Hypertension Unit and their impact on patient care.

To share insights from oncology nurses and support discussion on future cancer service planning and workforce needs policy.

To discuss the development of the next National Cancer Strategy & future of cancer care in Ireland.

Discussion related to the development of a national life sciences strategy, including policy coherence across health, enterprise and industrial policy; research and innovation capability; intellectual property protection; skills and workforce development; competitiveness and…

To highlight to the Department of Health the ‘Cancer Dashboard for Ireland’ developed by the Swedish Institute for Health Economics (IHE) with support from MSD which provides analysis of the state of cancer care in Ireland with focus on early detection, timely diagnosis, and…

Engagements during the US Chamber of Commerce visit to Dublin (23–26 February 2026) focused on Ireland’s competitiveness. Topics included patient access to innovative medicines, pharmaceutical pricing and reimbursement policy under the IPHA Framework Agreement 2026–2029, R&D and…

To highlight the importance for Ireland's new cardiac strategy to align with the policy priorities of the new EU Safe Harts Plan and to highlight the importance for routine cardiac health checks to be introduced in Ireland which encompass identification of LDL cholesterol as a…

To highlight the need for the INI report on an EU Cardiovascular Diseases Strategy to consider earlier and more consistent cardiovascular–renal–metabolic assessments, including baseline checks before age 35, earlier assessments for high risk groups, and structured follow up…

To discuss the ‘Cancer Dashboard for Ireland’ developed by the Swedish Institute for Health Economics (IHE) with support from MSD which provides analysis of the state of cancer care in Ireland with focus on early detection, timely diagnosis, and equitable access to effective…

To discuss with the Tánaiste and Minister for Finance Simon Harris (with IDA participation) the need to strengthen vaccine confidence, Ireland’s pro innovation policy environment, improve access to medicines, and elevate cardiovascular public health priorities across the EU,…

To discuss with the Minister for Enterprise (with IDA participation) MSD's footprint in Ireland, Ireland’s pro innovation policy environment, MFN and the changes underway globally, improving access to medicines in Ireland, Irelands EU Presidency, the establishment of an EU…

Increase awareness of combination therapies, rare diseases including orphan medicines and early access schemes for oncology/rare diseases.

Discussion health policy that relates to combination therapies, rare diseases including orphan medicines and early access in the Irish healthcare systems